IGC Key Statistics, Chart & Performance
The current stock price of IGC is 0.315 USD. In the past month the price decreased by -20.31%. In the past year, price decreased by -14.66%.
IGC Latest News, Press Relases and Analysis
IGC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.11 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 19.78 | 494.73B | ||
| MRK | MERCK & CO. INC. | 11.56 | 252.74B | ||
| PFE | PFIZER INC | 7.9 | 143.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.12B | ||
| ZTS | ZOETIS INC | 20.07 | 56.08B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.71 | 23.03B | ||
| VTRS | VIATRIS INC | 4.59 | 12.32B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.56 | 11.24B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.66 | 8.39B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.51B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.37B |
Related stock screener links
About IGC
Company Profile
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. The company is headquartered in Potomac, Maryland and currently employs 70 full-time employees. The company went IPO on 2006-04-13. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The firm operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. The company seeks to leverage artificial intelligence (AI) for Alzheimer's research.
Company Info
IGC PHARMA INC
10224 Falls Road
Potomac MARYLAND 20854 US
CEO: Ram Mukunda
Employees: 70
Phone: 13015294996
IGC PHARMA INC / IGC FAQ
What does IGC do?
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. The company is headquartered in Potomac, Maryland and currently employs 70 full-time employees. The company went IPO on 2006-04-13. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The firm operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. The company seeks to leverage artificial intelligence (AI) for Alzheimer's research.
What is the current price of IGC stock?
The current stock price of IGC is 0.315 USD. The price decreased by -1.28% in the last trading session.
What is the dividend status of IGC PHARMA INC?
IGC does not pay a dividend.
What is the ChartMill rating of IGC PHARMA INC stock?
IGC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does IGC PHARMA INC belong to?
IGC PHARMA INC (IGC) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the market cap for IGC PHARMA INC?
IGC PHARMA INC (IGC) has a market capitalization of 29.25M USD. This makes IGC a Nano Cap stock.
What is the outstanding short interest for IGC PHARMA INC?
The outstanding short interest for IGC PHARMA INC (IGC) is 0.34% of its float.
IGC Technical Analysis
IGC Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IGC. IGC may be in some trouble as it scores bad on both profitability and health.
IGC Financial Highlights
Over the last trailing twelve months IGC reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 58.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.16% | ||
| ROE | -79.66% | ||
| Debt/Equity | 0.02 |
IGC Forecast & Estimates
5 analysts have analysed IGC and the average price target is 3.7 USD. This implies a price increase of 1073.81% is expected in the next year compared to the current price of 0.315.
For the next year, analysts expect an EPS growth of 30.18% and a revenue growth 4.61% for IGC